Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model

Experimental Neurology

Volumn 247, Issue , 2013, Pages 45-58

  Febbraro, Fabia ^a,b   Andersen, Kathrine J ^a   Sanchez Guajardo, Vanesa ^a   Tentillier, Noemie ^a   Romero Ramos, Marina ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dopaminergic; Iron; MHCII; Microglia; Proteinase K; Recombinant adeno associated viral vector; T cells

Indexed keywords

ALPHA SYNUCLEIN; DEFEROXAMINE; PARVOVIRUS VECTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IRON CHELATION; LOCOMOTION; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; VALIDATION PROCESS;

DOPAMINERGIC; IRON; MHCII; MICROGLIA; PROTEINASE K; RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR; T CELLS;

ADMINISTRATION, INTRANASAL; ALPHA-SYNUCLEIN; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL LINE, TRANSFORMED; CORPUS STRIATUM; DEFEROXAMINE; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; FEMALE; FORELIMB; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SIDEROPHORES; TIME FACTORS; TRANSFECTION; TYROSINE 3-MONOOXYGENASE;

EID: 84876976065     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.03.017     Document Type: Article

References (80)

1. Azeredo da Silveira S., Schneider B.L., Cifuentes-Diaz C., Sage D., Abbas-Terki T., Iwatsubo T., Unser M., Aebischer P. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Genet. 2009, 18:872-887.
2. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?. Ann. Neurol. 1992, 31:119-130.
3. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 1991, 56:1441-1444.
4. Ben-Shachar D., Eshel G., Riederer P., Youdim M.B. Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Ann. Neurol. 1992, 32:S105-S110. (Suppl.).
5. Berg D., Gerlach M., Youdim M.B., Double K.L., Zecca L., Riederer P., Becker G. Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 2001, 79:225-236.
6. Borie C., Gasparini F., Verpillat P., Bonnet A.M., Agid Y., Hetet G., Brice A., Durr A., Grandchamp B. Association study between iron-related genes polymorphisms and Parkinson's disease. J. Neurol. 2002, 249:801-804.
7. Brittenham G.M., Griffith P.M., Nienhuis A.W., McLaren C.E., Young N.S., Tucker E.E., Allen C.J., Farrell D.E., Harris J.W. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N. Engl. J. Med. 1994, 331:567-573.
8. Brochard V., Combadiere B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., Bonduelle O., Alvarez-Fischer D., Callebert J., Launay J.M., Duyckaerts C., Flavell R.A., Hirsch E.C., Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009, 119:182-192.
9. Burger C., Gorbatyuk O.S., Velardo M.J., Peden C.S., Williams P., Zolotukhin S., Reier P.J., Mandel R.J., Muzyczka N. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 2004, 10:302-317.
10. Castellani R.J., Siedlak S.L., Perry G., Smith M.A. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. 2000, 100:111-114.
11. Chen L., Feany M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 2005, 8:657-663.
12. Cole N.B., Murphy D.D., Lebowitz J., Di Noto L., Levine R.L., Nussbaum R.L. Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. J. Biol. Chem. 2005, 280:9678-9690.
13. Conway K.A., Harper J.D., Lansbury P.T. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000, 39:2552-2563.
14. Cullen V., Lindfors M., Ng J., Paetau A., Swinton E., Kolodziej P., Boston H., Saftig P., Woulfe J., Feany M.B., Myllykangas L., Schlossmacher M.G., Tyynela J. Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol. Brain 2009, 2:5.
15. Davies P., Moualla D., Brown D.R. Alpha-synuclein is a cellular ferrireductase. PLoS One 2011, 6:e15814.
16. Decressac M., Ulusoy A., Mattsson B., Georgievska B., Romero-Ramos M., Kirik D., Bjorklund A. GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's disease. Brain 2011, 134:2302-2311.
17. Decressac M., Mattsson B., Bjorklund A. Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Exp. Neurol. 2012, 235:306-315.
18. Double K.L., Gerlach M., Youdim M.B., Riederer P. Impaired iron homeostasis in Parkinson's disease. J. Neural. Transm. Suppl. 2000, 37-58.
19. Ebeling W., Hennrich N., Klockow M., Metz H., Orth H.D., Lang H. Proteinase K from Tritirachium album Limber. Eur. J. Biochem. 1974, 47:91-97.
20. Febbraro F., Giorgi M., Caldarola S., Loreni F., Romero-Ramos M. alpha-Synuclein expression is modulated at the translational level by iron. NeuroReport 2012, 23:576-580.
21. Fine J.M., Baillargeon A.M., Renner D.B., Hoerster N.S., Tokarev J., Colton S., Pelleg A., Andrews A., Sparley K.A., Krogh K.M., Frey W.H., Hanson L.R. Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1alpha, and phosphorylates GSK3beta in P301L tau transgenic mice. Exp. Brain Res. 2012, 219:381-390.
22. Friedlich A.L., Tanzi R.E., Rogers J.T. The 5'-untranslated region of Parkinson's disease alpha-synuclein messenger RNA contains a predicted iron responsive element. Mol. Psychiatry 2007, 12:222-223.
23. Gaugler M.N., Genc O., Bobela W., Mohanna S., Ardah M.T., El-Agnaf O.M., Cantoni M., Bensadoun J.C., Schneggenburger R., Knott G.W., Aebischer P., Schneider B.L. Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol. 2012, 123:653-669.
24. Georgievska B., Kirik D., Bjorklund A. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J. Neurosci. 2004, 24:6437-6445.
25. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B. Altered brain metabolism of iron as a cause of neurodegenerative diseases?. J. Neurochem. 1994, 63:793-807.
26. Giasson B.I., Murray I.V., Trojanowski J.Q., Lee V.M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 2001, 276:2380-2386.
27. Golts N., Snyder H., Frasier M., Theisler C., Choi P., Wolozin B. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 2002, 277:16116-16123.
28. Gorbatyuk O.S., Li S., Sullivan L.F., Chen W., Kondrikova G., Manfredsson F.P., Mandel R.J., Muzyczka N. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:763-768.
29. Gotz M.E., Double K., Gerlach M., Youdim M.B., Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 2004, 1012:193-208.
30. Grenier D., Huot M.P., Mayrand D. Iron-chelating activity of tetracyclines and its impact on the susceptibility of Actinobacillus actinomycetemcomitans to these antibiotics. Antimicrob. Agents Chemother. 2000, 44:763-766.
31. Gundersen H.J., Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 1987, 147(Pt 3):229-263.
32. Guo C., Wang P., Zhong M.L., Wang T., Huang X.S., Li J.Y., Wang Z.Y. Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem. Int. 2013, 62:165-172.
33. Guo C., Wang T., Zheng W., Shan Z.Y., Teng W.P., Wang Z.Y. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 2013, 34:562-575.
34. Gutteridge J.M. Ageing and free radicals. Med. Lab. Sci. 1992, 49:313-318.
35. Hanson L.R., Roeytenberg A., Martinez P.M., Coppes V.G., Sweet D.C., Rao R.J., Marti D.L., Hoekman J.D., Matthews R.B., Frey W.H., Panter S.S. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J. Pharmacol. Exp. Ther. 2009, 330:679-686.
36. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. NeuroReport 1999, 10:717-721.
37. He Y., Thong P.S., Lee T., Leong S.K., Mao B.Y., Dong F., Watt F. Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic. Biol. Med. 2003, 35:540-547.
38. Hoepken H.H., Korten T., Robinson S.R., Dringen R. Iron accumulation, iron-mediated toxicity and altered levels of ferritin and transferrin receptor in cultured astrocytes during incubation with ferric ammonium citrate. J. Neurochem. 2004, 88:1194-1202.
39. Kaneko Y., Kitamoto T., Tateishi J., Yamaguchi K. Ferritin immunohistochemistry as a marker for microglia. Acta Neuropathol. 1989, 79:129-136.
40. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003, 37:899-909.
41. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 1998, 152:259-277.
42. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., Bjorklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 2002, 22:2780-2791.
43. Lundblad M., Decressac M., Mattsson B., Bjorklund A. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(9):3213-3219.
44. Marti M.J., Tolosa E., Campdelacreu J. Clinical overview of the synucleinopathies. Mov. Disord. 2003, 18(Suppl. 6):S21-S27.
45. Martin W.R., Wieler M., Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008, 70:1411-1417.
46. Matarredona E.R., Santiago M., Cano J., Machado A. Involvement of iron in MPP+ toxicity in substantia nigra: protection by desferrioxamine. Brain Res. 1997, 773:76-81.
47. McCormack A.L., Atienza J.G., Johnston L.C., Andersen J.K., Vu S., Di Monte D.A. Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J. Neurochem. 2005, 93:1030-1037.
48. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
49. Mehlhase J., Gieche J., Widmer R., Grune T. Ferritin levels in microglia depend upon activation: modulation by reactive oxygen species. Biochim. Biophys. Acta 2006, 1763:854-859.
50. Miake H., Mizusawa H., Iwatsubo T., Hasegawa M. Biochemical characterization of the core structure of alpha-synuclein filaments. J. Biol. Chem. 2002, 277:19213-19219.
51. Oakley A.E., Collingwood J.F., Dobson J., Love G., Perrott H.R., Edwardson J.A., Elstner M., Morris C.M. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007, 68:1820-1825.
52. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 1995, 15:3863-3875.
53. Oueslati A., Paleologou K.E., Schneider B.L., Aebischer P., Lashuel H.A. Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J. Neurosci. 2012, 32:1536-1544.
54. Palmer C., Roberts R.L., Bero C. Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats. Stroke 1994, 25:1039-1045.
55. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Academic Press, London.
56. Perry T.L., Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 1986, 67:269-274.
57. Reynolds A.D., Stone D.K., Hutter J.A., Benner E.J., Mosley R.L., Gendelman H.E. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J. Immunol. 2010, 184(5):2261-2271.
58. Ross O.A., Braithwaite A.T., Skipper L.M., Kachergus J., Hulihan M.M., Middleton F.A., Nishioka K., Fuchs J., Gasser T., Maraganore D.M., Adler C.H., Larvor L., Chartier-Harlin M.C., Nilsson C., Langston J.W., Gwinn K., Hattori N., Farrer M.J. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann. Neurol. 2008, 63:743-750.
59. Sanchez-Guajardo V., Febbraro F., Kirik D., Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One 2010, 5:e8784.
60. Santiago M., Matarredona E.R., Granero L., Cano J., Machado A. Neurotoxic relationship between dopamine and iron in the striatal dopaminergic nerve terminals. Brain Res. 2000, 858:26-32.
61. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
62. Serafin-Lopez J., Chacon-Salinas R., Munoz-Cruz S., Enciso-Moreno J.A., Estrada-Parra S.A., Estrada-Garcia I. The effect of iron on the expression of cytokines in macrophages infected with Mycobacterium tuberculosis. Scand. J. Immunol. 2004, 60:329-337.
63. Shachar D.B., Kahana N., Kampel V., Warshawsky A., Youdim M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 2004, 46:254-263.
64. Siglienti I., Bendszus M., Kleinschnitz C., Stoll G. Cytokine profile of iron-laden macrophages: implications for cellular magnetic resonance imaging. J. Neuroimmunol. 2006, 173:166-173.
65. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
66. Tanaka M., Sotomatsu A., Yoshida T., Hirai S., Nishida A. Detection of superoxide production by activated microglia using a sensitive and specific chemiluminescence assay and microglia-mediated PC12h cell death. J. Neurochem. 1994, 63:266-270.
67. Thomas B., Beal M.F. Hum. Mol. Genet. 2007, 16. (Spec No. 2:R183-194).
68. Thompson K.J., Shoham S., Connor J.R. Iron and neurodegenerative disorders. Brain Res. Bull. 2001, 55:155-164.
69. West M.J. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci. 1999, 22:51-61.
70. Wright J.A., Brown D.R. Alpha-synuclein and its role in metal binding: relevance to Parkinson's disease. J. Neurosci. Res. 2008, 86:496-503.
71. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
72. Xu L., Daly T., Gao C., Flotte T.R., Song S., Byrne B.J., Sands M.S., Parker Ponder K. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum. Gene Ther. 2001, 12:563-573.
73. Xu Q., Kanthasamy A.G., Reddy M.B. Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease. Toxicology 2008, 245:101-108.
74. Youdim M.B., Ben-Shachar D., Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?. Acta Neurol. Scand. Suppl. 1989, 126:47-54.
75. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5:863-873.
76. Zhang Z., Zhang F., An P., Guo X., Shen Y., Tao Y., Wu Q., Zhang Y., Yu Y., Ning B., Nie G., Knutson M.D., Anderson G.J., Wang F. Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses. Blood 2011, 118:1912-1922.
77. Zhu W., Xie W., Pan T., Xu P., Fridkin M., Zheng H., Jankovic J., Youdim M.B., Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 2007, 21:3835-3844.
78. Zhu W., Li X., Xie W., Luo F., Kaur D., Andersen J.K., Jankovic J., Le W. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol. Dis. 2010, 37:307-313.
79. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., Summerford C., Samulski R.J., Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999, 6:973-985.
80. Zolotukhin S., Potter M., Zolotukhin I., Sakai Y., Loiler S., Fraites T.J., Chiodo V.A., Phillipsberg T., Muzyczka N., Hauswirth W.W., Flotte T.R., Byrne B.J., Snyder R.O. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002, 28:158-167.